Founder & CSO, Selexagen Therapeutics, Inc.
Dr. O’Connor is a leader in the field of oncology drug discovery and development. His contributions include over 100 publications and patents, and over 20 compounds brought into development (e.g., Axitinib (VEGF, PII/PIII), AG14699/PF-01367338 (PARP, PII/III), Crizotinib (C-Met/ALK, PII/III)), RDEA119/BAY869766 (MEK, Phase I/II). Prior to joining the industry, Dr. O’Connor spent 10 years at the National Cancer Institute in Bethesda, Maryland. He then joined Agouron Pharmaceuticals which was later acquired by Pfizer, Inc. at which he became the Head of Oncology Research. Dr. O’Connor has also contributed research or scientific advisory board duties at Ardea Biosciences, Halozyme Therapeutics and Ruga Corporation. Dr. O’Connor is currently a Senior Editor of the journal Cancer Research, and Founder & Chief Scientific Officer of Selexagen Therapeutics, Inc.